Ausgewählte Publikationen

Boeck S, Haas M*, Laubender RP*, Kullmann F, Klose C, Bruns CJ, Wilkowski R, Stieber P, Holdenrieder S, Buchner H, Mansmann U, Heinemann V (2010)

Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res 16 (3): 986-994 (*contributed equally)


Parmar S, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kächele V, Seeringer A, Paul T, Seufferlein T, Stingl JC (2013)

Pharmacogenetic predictors for EGFR inhibitor associated skin toxicity. Pharmacogenomics J 13 (2): 181-188


Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens M, Gauler TC, Märten A, Klein S, Kojouharoff G, Barner M, Geissler M, Greten TF, Mansmann U, Kirchner T, Heinemann V (2013)

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, cross-over phase 3 trial AIO-PK0104. Br J Cancer 108 (2): 469-476


Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, Holdenrieder S, Modest DP, Schulz C, Boeck S (2013)

Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: Results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 139 (4): 681-689


Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Ormanns S, Haas M, Modest DP, Kirchner T, Heinemann V (2013)

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. J Gastroenterol 48 (4): 544-548


Boeck S, Wittwer C, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S (2013) Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Br J Cancer 108 (8): 1684-1694


Wittwer C*, Boeck S*, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S (2013)

Circulating nucleosomes and immunogenic cell death markers HMGB1, RAGE, DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer 133 (11): 2619-2630 (*contributed equally)


Ormanns S, Heinemann V, Raponi M, Isaacson J, Laubender RP, Haas M, Kruger S, Kleespies A, Mann E, Kirchner T, Boeck S (2014)

Human equilibrative nucleoside transporter 1 (hENT1) is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. Eur J Cancer 50 (11): 1891-1899


Paul T, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kächele V, Steffens M, Scholl C, Hichert V, Seufferlein T, Stingl JC (2014)

Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. Eur J Cancer 50 (11): 1855-1863


Ormanns S, Assmann G, Reu S, Gallmeier E, Bader DC, Kleespies A, Haas M, Kruger S, Heinemann V, Kirchner T, Boeck S (2014)

ALK expression is absent in pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol 140 (9): 1625-1628


Ormanns S, Siveke JT, Heinemann V, Haas M, Sipos B, Schlitter AM, Esposito I, Jung A, Laubender RP, Kruger S, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Geissler M, Greten TF, Kirchner T, Boeck S (2014)

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer 14: 624

  Verantwortlich für den Inhalt: Prof. Dr. V. Heinemann; Stand: 29.01.2015